| Market Cap | 391.82M | P/E | 4.09 | EPS this Y | -147.10% | Ern Qtrly Grth | - |
| Income | 9.02M | Forward P/E | -4.25 | EPS next Y | -29.30% | 50D Avg Chg | -19.00% |
| Sales | 143.77M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 9.00% |
| Dividend | N/A | Price/Book | 1.80 | EPS next 5Y | - | 52W High Chg | -37.00% |
| Recommedations | 1.80 | Quick Ratio | 9.33 | Shares Outstanding | 54.53M | 52W Low Chg | 89.00% |
| Insider Own | 16.86% | ROA | -1.11% | Shares Float | 36.25M | Beta | 0.91 |
| Inst Own | 69.39% | ROE | 3.38% | Shares Shorted/Prior | 4.25M/4.18M | Price | 9.00 |
| Gross Margin | 21.29% | Profit Margin | 6.28% | Avg. Volume | 670,651 | Target Price | 17.63 |
| Oper. Margin | -50.80% | Earnings Date | Nov 4 | Volume | 260,472 | Change | -2.17% |
Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| PFREUNDSCHUH PETER P. | Chief Financial Offi.. Chief Financial Officer | Oct 03 | Sell | 6.99 | 13,567 | 94,833 | 149,433 | 10/05/23 |
| Carter Todd Alfred | Chief Scientific Off.. Chief Scientific Officer | Sep 15 | Sell | 8.16 | 10,500 | 85,680 | 54,360 | 09/18/23 |
| Carter Todd Alfred | Chief Scientific Off.. Chief Scientific Officer | Sep 15 | Option | 2.85 | 5,000 | 14,250 | 64,860 | 09/18/23 |
| Carter Todd Alfred | Chief Scientific Off.. Chief Scientific Officer | Jul 06 | Sell | 10.80 | 5,500 | 59,400 | 59,860 | 07/10/23 |
| Sandrock Alfred | President and CEO President and CEO | Apr 03 | Sell | 7.83 | 7,437 | 58,232 | 214,618 | 04/05/23 |
| NEUROCRINE BIOSCIENCES INC | 10% Owner 10% Owner | Feb 23 | Buy | 8.88 | 4,395,588 | 39,032,821 | 8,575,316 | 02/24/23 |
| Hesslein Robert W. | Senior VP & General.. Senior VP & General Counsel | Feb 17 | Sell | 7.45 | 3,297 | 24,563 | 106,610 | 02/22/23 |
| Carter Todd Alfred | Chief Scientific Off.. Chief Scientific Officer | Feb 17 | Sell | 7.45 | 738 | 5,498 | 67,553 | 02/22/23 |
| Carter Todd Alfred | Chief Scientific Off.. Chief Scientific Officer | Feb 13 | Sell | 7.67 | 797 | 6,113 | 34,291 | 02/15/23 |
| Hesslein Robert W. | Senior VP & General.. Senior VP & General Counsel | Feb 13 | Sell | 7.67 | 2,868 | 21,998 | 109,907 | 02/15/23 |
| Third Rock Ventures III, L.P. | 10% Owner 10% Owner | Jan 30 | Sell | 9.2 | 388,642 | 3,575,506 | 4,685,291 | 02/01/23 |
| Third Rock Ventures III, L.P. | 10% Owner 10% Owner | Jan 24 | Sell | 9.25 | 150,000 | 1,387,500 | 5,123,933 | 01/26/23 |
| Third Rock Ventures III, L.P. | 10% Owner 10% Owner | Jan 20 | Sell | 9.11 | 155,000 | 1,412,050 | 5,273,933 | 01/24/23 |
| EcoR1 Capital, LLC | 10% Owner 10% Owner | Jan 09 | Sell | 8.07 | 902,400 | 7,282,368 | 3,851,507 | 01/11/23 |
| PIERCE GLENN | Director Director | Jul 14 | Sell | 6.70 | 9,512 | 63,730 | 16,788 | 07/18/22 |
| Higgins Michael J | Director Director | Jul 14 | Sell | 6.70 | 13,891 | 93,070 | 31,314 | 07/18/22 |
| EcoR1 Capital, LLC | 10% Owner 10% Owner | Jun 21 | Buy | 5.47 | 477,400 | 2,611,378 | 4,753,907 | 06/23/22 |
| Swartz Robin | Chief Operating Offi.. Chief Operating Officer | Apr 04 | Sell | 8.25 | 1,527 | 12,598 | 52,060 | 04/06/22 |
| Hesslein Robert W. | Senior VP & General.. Senior VP & General Counsel | Apr 04 | Sell | 8.25 | 2,786 | 22,984 | 114,963 | 04/06/22 |
| Swartz Robin | Chief Operating Offi.. Chief Operating Officer | Mar 21 | Sell | 8.49 | 4,413 | 37,466 | 53,587 | 03/23/22 |
| Hesslein Robert W. | Senior VP & General.. Senior VP & General Counsel | Mar 21 | Sell | 8.49 | 4,955 | 42,068 | 117,749 | 03/23/22 |
| Burek Julie | VP, Finance VP, Finance | Mar 21 | Sell | 8.49 | 2,649 | 22,490 | 52,458 | 03/23/22 |
| Burek Julie | VP, Finance VP, Finance | Jan 03 | Sell | 2.95 | 3,328 | 9,818 | 46,257 | 01/14/22 |